Pharma, Olysio sales boost J&J 1Q earnings
This article was originally published in Scrip
Executive Summary
Pharmaceuticals maintained their growing importance to Johnson & Johnson's bottom line in the first quarter of 2014 as prescription drug sales grew in the double digits while medical device and diagnostic (MD&D) sales stabilized and revenue from over-the-counter medicines and other consumer health products declined.